- Home
- ALX vs XNCR Comparison
ALX vs XNCR Comparison
Compare ALX & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALX | XNCR |
|---|---|---|
| Founded | 1928 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 928.3M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | ALX | XNCR |
|---|---|---|
| Price | $241.70 | $12.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $22.78 |
| AVG Volume (30 Days) | 76.8K | ★ 703.5K |
| Earning Date | 02-09-2026 | 02-26-2026 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.14 | N/A |
| Revenue | ★ $215,838,000.00 | $150,132,000.00 |
| Revenue This Year | N/A | $18.68 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.40 | ★ N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $185.75 | $6.92 |
| 52 Week High | $260.84 | $21.00 |
Technical Indicators
Market Signals| Indicator | ALX | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 68.81 | 35.62 |
| Support Level | $224.33 | $12.41 |
| Resistance Level | $250.61 | $13.75 |
| Average True Range (ATR) | 8.14 | 0.81 |
| MACD | 1.86 | -0.13 |
| Stochastic Oscillator | 79.80 | 8.36 |
Price Performance
Historical ComparisonAbout ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.